by David Wallace A New Year, a New Perspective As 2025 begins, I’ve been reflecting on the unpredictable journey of aging—a path that’s less about smooth sailing and more about navigating challenges. After four years living in remission from polycythemia vera (PV), I’ve come to understand that maintaining good health requires resilience to overcome challenges […]
A Promising Drug for Breast Cancer Shows Potential to Treat MPN Blood Cancers
by David Wallace Researchers have discovered a new therapeutic avenue targeting a protein called RSK1 (ribosomal protein S6 kinase A1), which could revolutionize treatment for blood cancers such as Myeloproliferative Neoplasms (MPN) and secondary Acute Myeloid Leukemia (sAML). This protein plays a crucial role in driving cancer progression and inflammation. The Drug’s Mechanism The investigational […]
How Does Polycythemia Vera Differ from Polycythemia?
by David Wallace Updated July 20, 2026 Polycythemia is defined as having an abnormally high number of red blood cells in the blood—derived from the Latin “poly” (many), “cyte” (cell), and “hemo” (blood). This general term encompasses various conditions leading to this hematological abnormality. Polycythemia Vera (PV) fits under this umbrella but has its own […]
New Scoring Model Improves Prediction of Outcomes in Essential Thrombocythemia
by David Wallace Summary: Researchers have developed a new Essential Thrombocythemia scoring system called the “triple A” (AAA) model to predict outcomes in patients with essential thrombocythemia (ET), a type of blood cancer. This model uses three simple factors: age, absolute neutrophil count, and absolute lymphocyte count to categorize patients into different risk groups. The […]
MPNs and Dementia Risk: New Study Finds Link Between Myeloproliferative Neoplasms and Cognitive Decline
by David Wallace A new study published in the European Journal of Haematology has uncovered a significant association between blood cancers known as myeloproliferative neoplasms (MPNs) and an increased risk of dementia. This Danish population-based cohort study, spanning over two decades, provides valuable insights into the long-term neurological impacts of chronic blood cancers and inflammation […]
The Unseen Journey: Bringing MPNs to Life with Generative AI
Sponsored Post Like countless busy parents juggling family responsibilities, when Ben began experiencing unexplained symptoms – such as headaches, fatigue and brain fog – he initially pushed them aside. Clarity only came when a physical exam for a new job uncovered something was wrong. Ben’s tests revealed he had an unexpectedly high platelet count. A […]
September is Blood Cancer Awareness Month for MPNs
by Lou Ann Donovan and David Wallace National Blood Cancer Awareness Month: Spotlight on Myeloproliferative Neoplasms September marks National Blood Cancer Awareness Month, an annual event established by Congress in 2010 to shed light on various blood diseases, including the lesser-known chronic blood cancers called Myeloproliferative Neoplasms (MPNs). The statistics are sobering: every three minutes, […]
What Are The Key Factors in Predicting Polycythemia Vera Progression?
by David Wallace A new study has shed light on the factors that may predict polycythemia vera (PV) disease progression. The REVEAL study, presented at the 2024 European Hematology Association Congress, has identified five key characteristics that could help doctors better understand which patients are at higher risk of their condition worsening over time. Polycythemia […]
Help advance Myelofibrosis research from home
PV Reporter, in partnership with Sanguine Biosciences, is reaching out to raise awareness about an at-home research opportunity for patients diagnosed with Myelofibrosis. What is the goal of the at-home research? The goal of this research is to enhance their understanding of Myelofibrosis, in support of developing new diagnostic and treatment options for patients living […]
Precision Medicine in Myeloproliferative Neoplasms (MPNs): Molecular Insights and Advances
Simple Summary Myeloproliferative neoplasms (MPNs) represent a group of blood cancers characterized by the excessive production of blood cells in the bone marrow, including Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (PMF). Recent advancements in the field of molecular biology have significantly enhanced our understanding of the genetic underpinnings of these conditions. The […]
